Skip to search formSkip to main contentSkip to account menu

technetium Tc 99m depreotide

Known as: Tc-99m depreotide, Technetium Tc-99m Depreotide, technetium (99mTc) depreotide 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
The (99m)Tc-labeled agent, ((99m)TcO)depreotide, has received regulatory approval in the United States and Europe for use in the… 
2011
2011
Previous reports suggested the accumulation of technetium-99m-depreotide trifluoroacetate ((99m)Tc-D) at the sites of active… 
2010
2010
ObjectivePrevious studies have demonstrated the feasibility of targeting lymphoma lesions with somatostatin receptor binding… 
2010
2010
Previous studies have demonstrated the feasibility of targeting lymphoma lesions with somatostatin receptor binding agents… 
2008
2008
UNLABELLED At present also radionuclide methods are used to diagnose pulmonary malignancies. One of them is solitary pulmonary… 
2005
2005
PurposeThe aim of this study was to evaluate the clinical usefulness of scintigraphy with 99mTc-depreotide in the assessment of… 
Review
2004
Review
2004
Background99mTc-depreotide (NeoTect) is a synthetic somatostatin analogue, which binds to somatostatin receptor (SSTR) subtypes 2… 
2004
2004
Somatostatin receptor scintigraphy (SRS) is useful in diagnosing tumours with increased expression of somatostatin receptors… 
2004
2004
PurposeScintigraphy with 99mTc-depreotide, a somatostatin analogue–technetium ligand, has been used for evaluation of various… 
2004
2004
We read the short communication by Kainz et al. [1] with great interest. We are aware of the pioneering work of the research…